Search results
Results from the WOW.Com Content Network
In cancer, loss of feedback restriction between transcription factors can lead to increased local PD-L1 expression, which could limit the effectiveness of systemic treatment with agents targeting PD-L1. [28] CAR-T [29] and NK cells [30] targeting PD-L1 are being evaluated for treating cancer. pSTAT-1 and PDL-1 expressions also strongly ...
In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals to prevent the immune system from attacking the tumor cells. [9] Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way. [ 9 ]
PD-L1 expression on the surface on cancer cells plays a significant role. PD-L1 positive tumors were twice as likely to respond to combination treatment. [38] [37] However patients with PD-L1 negative tumors also have limited response to anti-PD1, demonstrating that PD-L1 expression is not an absolute determinant of the effectiveness of therapy ...
Among PD-L1 functions is a key regulatory role on T cell activities. It appears that (cancer-mediated) upregulation of PD-L1 on the cell surface may inhibit T cells that might otherwise attack. PD-L1 on cancer cells also inhibits FAS- and interferon-dependent apoptosis, protecting cells from cytotoxic molecules produced by T cells.
Cancer cells avoid immune destruction by escaping detection. One of the main ways is by expressing the programmed death-1 ligand (PD-L1) on their surface.This protein is usually used to prevent T cells from attacking healthy cells. Tumor cells express PD-L1 in high amounts which prevents T cells from attacking them.
The expression of PD-L1 (programmed death-ligand 1; one of the immune checkpoints) has been demonstrated to be a good biomarker of PD-L1 blockade therapy in some cancers. [10] However, there is a need for better biomarkers as there are some predictive errors with PD-L1 expression. [10]
In lung cancer, Trodelvy continues to be evaluated in combination with pembro in first-line PD-L1 high metastatic nonsmall cell lung cancer in the phase 3 EVOKE-03 study. ... There's clear Trop-2 ...
Non-small cell lung cancer (NSCLC) cells expressing programmed death-ligand 1 (PD-L1) could interact with programmed death receptor 1 (PD-1) expressed on the surface of T cells, and result in decreased tumor cell kill by the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody.